Roche and partner Alnylam said their experimental high blood pressure drug showed an effect when used in combination with standard care in a phase 2 study.
Full results of the Phase 2 KARDIA-2 study, testing the twice-yearly injectable zilebesiran, will be presented at the American College of Cardiology’s annual scientific meeting in Atlanta on April 6, Roche said in a statement on Tuesday.
In July last year, Roche agreed to develop and commercialize Alnylam’s zilebesiran to treat hypertension, the leading cause of cardiovascular disease worldwide.
At the time, Roche paid Alnylam $310 million up front, with milestones raising the potential value of the deal to $2.8 billion in a big bet that it could meet demand beyond existing cheap generic blood pressure drugs.
